Mirum Pharmaceuticals (MIRM) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 98.6% versus a gain of 11.7%. Over five years, MIRM leads with a +375.2% price change compared with +112.4% for TVTX. Mirum Pharmaceuticals is the larger company by market cap ($5.28 billion vs $4.91 billion), about 1.1 times the size, while Travere Therapeutics is growing revenue faster (+110.5% vs +54.7%).
Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -5.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRM | TVTX |
|---|---|---|
| Share price | $81.35 | $52.04 |
| Market cap | $5.28B | $4.91B |
| 1-day change | +0.88% | -2.62% |
| YTD return | +2.99% | +36.19% |
| 1-year return | +11.67% | +98.63% |
| 5-year return | +375.18% | +112.41% |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-14.10 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $521.31M | $490.73M |
| Revenue growth (YoY) | +54.74% | +110.45% |
| Net income (latest FY) | $-23.36M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | -4.25% | -12.80% |
| Net margin | -4.48% | -5.21% |
| 52-week high | $130.00 | $68.73 |
| 52-week low | $63.23 | $22.59 |
| Distance from 52-week high | -37.42% | -24.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +79.21% | +44.52% |
| Average volume | 695.76K | 1.59M |
| Shares outstanding | 64.93M | 94.26M |
| Employees | 433 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed MIRM by 87.0 percentage points over the past year.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +54.74%).
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
MIRM vs TVTX FAQ
Which is bigger, Mirum Pharmaceuticals or Travere Therapeutics?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.28B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, MIRM or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +11.67% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Mirum Pharmaceuticals and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.